Introduction
Many of the HIV-infected individuals who inject intravenous drugs consume morphine, heroin or related substances. There is conflicting data on the impact of opioids on HIV disease progression. Whereas in vitro studies suggest a potential link between opioid exposure and elevated virus replication or decreased immune function[
1‐
5], most of epidemiological and clinical studies do not find a correlation between opioid intake and progression of HIV infection[
6‐
12]. In order to reconcile these conflicting data, we performed
in vitro experiments studying the effects of opioids (heroin and morphine) on HIV replication in the chronically-infected CD4-positive T cell line ACH-2[
13]. CD4-positive T cells represent the cellular reservoir in which HIV is harbored predominantly in the body and they contribute to most of the viral replication detected in the blood plasma[
14‐
16].
Discussion
Opioid-mediated reactivation of latent HIV infection in our model was observed at concentrations in the lower millimolar range. Since opioids are common in the HIV-risk group of injecting drug users (IDUs), this activity might influence the pathogenesis of HIV infection in this group of patients. However, plasma concentrations of heroine in IDUs are in the range of 1–10 μM[
19] and even maximum plasma concentrations are only in the range of 1500–3900 ng/ml (reviewed in[
20]), which corresponds to 4.1-10.7 μM (calculated with a molar weight of 369.41 g/mol). Secondly plasma-concentrations of medically administered morphine and its modern derivates for means of analgesia remain well below those ranges of reactivating effects[
21‐
23]. These
in vivo concentrations are 2–3 orders of magnitude lower than the
in vitro concentration at which we observed a stimulating effect. It therefore seems very unlikely that the here-described opioid-mediated reactivation of HIV may have any influence on HIV replication
in vivo.
Opioid-triggered reactivation of HIV replication in latently-infected cells has been described in the monocytic cell line U1[
3]. HIV reactivation after treatment with morphine was observed in the picomolar (10
-12) range but not at higher concentrations. Especially at micromolar concentrations – the concentration range of plasma levels found in drug abusers - no effects were observed[
3]. Similar effects were reported from the same group when studying productive infection in cultured peripheral blood lymphocytes[
4]. In studies with experimental SHIV-infection in the rhesus macaque model, elevated viral load was reported in morphine-treated animals (n = 6) versus untreated animals (n = 3)[
2]. Recently, a decrease in anti-HIV microRNA expression was reported in monocytes following treatment with morphine and heroin[
5], suggesting a potential explanation for the increased viral replication found in
in vitro studies.
In contrast, the majority of epidemiological studies does not show negative effects of drug abuse on HIV progression[
8‐
12], but many confounding variables such as the pattern of drug use may make it difficult to clearly interpret this data. To address this, a prospective clinical study with a total of 1148 participants was performed, in which the effects of hard drug use (opioids or cocaine) on HIV disease parameters was studied[
6]. Drug use had no effect on HIV viral load or CD4 cell counts (n = 613 versus n = 535). In line with this, no effects of drug use on viral load have been observed in a seroconverter study with 60 injection drug users in a total of 149 participants[
7].
The literature therefore seems to be divided into experimental and
in vitro studies reporting enhancement of HIV infection following treatment with opioids and
in vivo studies not finding such a correlation. We suggest that this difference, at least in parts, relates to the concentration range at which effects were observed: All
in vitro studies reporting an HIV-activating effect of opioids in cell culture found these effects at very low concentrations and no activity was observed at relevant plasma concentrations[
3‐
5]. Moreover, all so-far reported
in vitro data were generated in monocytes[
3,
5] (or in PBMC containing monocytes[
4]), whereas more than 99% of HIV particles detected in the human plasma originate from T-lymphocytes[
15,
24,
25]. Hence, effects found in monocytes
in vitro may not be representative for the lymphocyte-driven plasma viral load
in vivo. Our
in vitro- results indicate that there is an HIV-stimulating effect of opioids also in T cells, but only at concentrations that are far above relevant
in vivo-concentrations. The molecular mechanism of HIV latency in the ACH-2 cell line used in our study is caused by a defect in the Tat/TAR axis[
26] and the same mechanism of latency is also frequently found in latently-infected primary T cells isolated from HIV patients[
27].
Taken together, the literature seems to be divided into in vitro studies reporting enhancement of HIV infection following treatment with opioids and in vivo studies not finding such a correlation. Our in-vitro results indicate that there is an HIV-stimulating effect of opioids in latently-infected T cells, but only at concentrations that are far beyond relevant in vivo-concentrations and our findings may therefore contribute to reconcile the apparently conflicting data of in vitro and in vivo research. Our data provides no evidence that the medical use of opioids for indications of anesthesia and analgesia in HIV-infected patients may have any side effects on HIV replication.
Materials and methods
Cell culture
A3.01 (human CD4 + -T-lymphoblasts, NIAID) and ACH-2 (latently HIV-infected A3.01, Folks 1989, NIAID) were cultured in standard tissue flasks using RPMI-medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% FCS (Linaris, Bettingen, Germany) at 37°C and 5% CO2 atmosphere. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll/Paque density-separation centrifugation from human whole blood donated by healthy volunteers. For the different experiments 105 cells per well were cultured in flat-bottom 96 well plates in a total volume of 200 μl for 24 h in the absence or presence of the indicated substances.
Opioids, antagonists and other reagents
Morphine and Heroine were obtained from the University of Wurzburg’s Department of Forensic Medicine. The Use and Discard of those substances were documented in accordance with the German Narcotics Act. Naloxone, Glutathion and N-Acetylcysteine were purchased through Sigma, St.Lewis, MO.
Flow cytometry
Reactivation of HIV in ACH-2 cells was quantified by the expression of viral p24-antigen detected by flow cytometry (Becton-Dickinson, Heidelberg, Germany). Cells were fixated for 20 min with 4% formalin in PBS and later permeabilized with 0.5% saponin in PBS/5%BSA. The following antibodies were used: 183-H12-5C-anti-HIV-p24-mouse-antibody and goat-anti-mouse antibodies conjugated with FITC or PE (BD Biosciences). Cell death in uninfected A3.01 cells was quantified by 7-AAD staining according to the instructions of the manufacturer (BD Biosciences). Besides staining with 7-AAD, necrotic cells also displayed a characteristic shift in a forward-scatter (FSC)/sideward scatter (SSC) dot plot. This shift was used to quantify necrotic cells also for HIV-infected ACH-2 cells, for which a 7-AAD staining was not possible for safety reasons (7-AAD staining requires nonfixated cells which in case of ACH-2 cells would contaminate the flow cytometer with HIV).
Competing interests
All of the authors declare that they have no competing interests.
Authors’ contributions
CS conceived of the study and helped to draft the manuscript. JP conducted the study, performed the statistical analysis and is the main author of the manuscript. EK participated in the study’s design and helped to draft the manuscript. All authors read and approved the final manuscript.